MedTrace Logo

Assessment of Paclitaxel-Induced Neuropathy

NCT01953159 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2025-06-08

No results posted yet for this study

Summary

The purpose of this study is to collect clinical data, blood samples, and self reported symptoms from patients that experience unusually severe neuropathy after treatment with paclitaxel. This data will be used to develop predictive markers for neuropathy. Blood samples will be used to create induced pluripotent stem (iPS) cells and eventually artificial nerve cells to be used to study neuropathy in the lab.

Conditions

Interventions

OTHER

Blood Collection

OTHER

Patient Questionnaires

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Gini Fleming, MD · University of Chicago

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-29
Primary Completion
2027-05-19
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01953159 on ClinicalTrials.gov